logo
logo
Sign in

Bioprocess Containers Market worth $9.6 billion by 2026 - Exclusive Report by MnM

avatar
Nilkanth Rathod
Bioprocess Containers Market worth $9.6 billion by 2026 - Exclusive Report by MnM

Growth in the bioprocess containers market is mainly driven by factors such as the growing biologics market, affordability and sustainability of single-use bioprocess technologies, and rising biopharmaceutical R&D. Emerging countries and the patent expiry of biologics are expected to offer growth opportunities for players operating in the bioprocess containers market during the forecast period.  

With the World Health Organization (WHO) officially declared the outbreak of the virus as a pandemic, a mix of established pharmaceutical companies, as well as players in the bioprocess containers market, have stepped forward to develop treatments and vaccines that target the infection caused by the novel coronavirus. 

Since most of the leading COVID-19 vaccine programs are using novel approaches, including mRNA, DNA vaccine, and vectors, these platforms are largely built on single-use technology. Most of the pandemic-related new facilities are largely engaging single-use systems due to their flexibility combined with high speed and much lower capital investment compared to traditional stainless steel equipment.

Therefore, the growing adoption of single-use technologies for COVID-19 pandemic-related research, coupled with increasing vaccine development by key players, is expected to have a positive impact on the bioprocess containers market. 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107645832

The growth of single-use technologies can be attributed to the growing need for better, cheaper, and faster biologics production. Active development of individualized biologics and personalized medicines, including patient-specific cellular & gene therapies and therapeutic vaccines, demands high sterility and is therefore manufactured using single-use equipment and consumables.  

More biologics having higher potency that require smaller production volumes, advancements in biosimilars targeting smaller markets, and ongoing improvements in production yields and efficiencies that create production operations at much smaller scales have increased the use of single-use technologies such as single-use bioprocess containers/bags as they are best suited for small volume productions. However, single-use technologies are now slowly moving towards clinical production and commercial operations. 

Growth in the biologics market is mainly driven by monoclonal antibodies and human insulin, which are among the leading contributors to the bioprocess containers market. Additionally, the Centre for Biologics Evaluation and Research’s (CBER) (2021-25) strategic plan involves various schemes for boosting the growth of the biologics market. 

Key Market Players

The bioprocess containers market is dominated by a few globally established players such as Sartorius Stedim Biotech (France), Thermo Fisher Scientific (US), Danaher Corporation (US), and Merck Millipore (Germany).

collect
0
avatar
Nilkanth Rathod
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more